NO20015932L - Fremgangsmåte til å behandle diabetes - Google Patents

Fremgangsmåte til å behandle diabetes

Info

Publication number
NO20015932L
NO20015932L NO20015932A NO20015932A NO20015932L NO 20015932 L NO20015932 L NO 20015932L NO 20015932 A NO20015932 A NO 20015932A NO 20015932 A NO20015932 A NO 20015932A NO 20015932 L NO20015932 L NO 20015932L
Authority
NO
Norway
Prior art keywords
type
diabetes
symptoms
procedures
treating diabetes
Prior art date
Application number
NO20015932A
Other languages
English (en)
Other versions
NO20015932D0 (no
NO324117B1 (no
Inventor
Andreas Sommer
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Publication of NO20015932D0 publication Critical patent/NO20015932D0/no
Publication of NO20015932L publication Critical patent/NO20015932L/no
Publication of NO324117B1 publication Critical patent/NO324117B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20015932A 1999-06-04 2001-12-04 Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes. NO324117B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/326,189 US6040292A (en) 1999-06-04 1999-06-04 Methods for treating diabetes
PCT/US2000/014163 WO2000074710A2 (en) 1999-06-04 2000-05-23 Methods for treating diabetes

Publications (3)

Publication Number Publication Date
NO20015932D0 NO20015932D0 (no) 2001-12-04
NO20015932L true NO20015932L (no) 2002-01-31
NO324117B1 NO324117B1 (no) 2007-08-27

Family

ID=23271175

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015932A NO324117B1 (no) 1999-06-04 2001-12-04 Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes.

Country Status (16)

Country Link
US (1) US6040292A (no)
EP (1) EP1183042B1 (no)
JP (1) JP2003501397A (no)
KR (1) KR100694737B1 (no)
CN (1) CN1235637C (no)
AT (1) ATE271880T1 (no)
AU (1) AU780400B2 (no)
CA (1) CA2373281C (no)
DE (1) DE60012517T2 (no)
ES (1) ES2222208T3 (no)
HK (1) HK1044895A1 (no)
IL (1) IL146868A0 (no)
MX (1) MXPA01013384A (no)
NO (1) NO324117B1 (no)
WO (1) WO2000074710A2 (no)
ZA (1) ZA200110408B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
MY137552A (en) * 2000-07-03 2009-02-27 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20030035788A1 (en) * 2000-09-19 2003-02-20 Desmond Mascarenhas Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
WO2006074091A2 (en) * 2004-12-30 2006-07-13 Hill's Pet Nutrition, Inc. Compositions for feline consumption
EP2148695B1 (en) * 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity
EP2352514A4 (en) 2008-10-29 2012-07-25 Univ Rockefeller METHOD AND KIT FOR DISEASE TREATMENT BY ADMINISTRATION OF THE PROTEIN BINDING TO AN INSULINARY GROWTH FACTOR 2
AR075998A1 (es) 2009-04-01 2011-05-11 Genentech Inc Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
TR201809456T4 (tr) 2010-08-16 2018-07-23 Allergan Inc Alfa-2b adrenerjik reseptör agonistleri olan düzenleyici t hücrelerini aktifleştirme metodu.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
GB9217696D0 (en) * 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
JPH08500123A (ja) * 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
WO1995003817A1 (en) * 1993-08-03 1995-02-09 Celtrix Pharmaceuticals, Inc. Method of treating reproductive disorders
ATE297214T1 (de) * 1993-09-20 2005-06-15 Celtrix Pharma Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
CA2176708A1 (en) * 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders
JPH10512235A (ja) * 1994-07-20 1998-11-24 セルトリックス ファーマシューティカルズ，インコーポレイテッド 骨形成の促進および骨再造形の調節のためのｉｇｆ／ｉｇｆｂｐ複合体
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes

Also Published As

Publication number Publication date
EP1183042B1 (en) 2004-07-28
CN1387440A (zh) 2002-12-25
CA2373281A1 (en) 2000-12-14
WO2000074710A3 (en) 2001-06-28
JP2003501397A (ja) 2003-01-14
KR20020020723A (ko) 2002-03-15
DE60012517T2 (de) 2005-08-04
IL146868A0 (en) 2002-08-14
AU5041100A (en) 2000-12-28
HK1044895A1 (en) 2002-11-08
US6040292A (en) 2000-03-21
NO20015932D0 (no) 2001-12-04
DE60012517D1 (de) 2004-09-02
CA2373281C (en) 2010-01-12
NO324117B1 (no) 2007-08-27
ATE271880T1 (de) 2004-08-15
KR100694737B1 (ko) 2007-03-14
EP1183042A2 (en) 2002-03-06
AU780400B2 (en) 2005-03-17
WO2000074710A2 (en) 2000-12-14
CN1235637C (zh) 2006-01-11
ZA200110408B (en) 2003-03-19
ES2222208T3 (es) 2005-02-01
MXPA01013384A (es) 2003-09-04

Similar Documents

Publication Publication Date Title
NO20015932D0 (no) Fremgangsmåte til å behandle diabetes
PT1409006E (pt) Misturas monodispersas e métodos de tratamento de diabetes
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
MY137350A (en) Glucagon-like peptide-1 analogs
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
NO20003051L (no) Metode for administrering av AspB28-humant insulin
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
AU6323001A (en) Treatment of acute coronary syndrome with glp-1
RS20050035A (en) Therapies for renal failure using interferon-betha
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
HK1052139A1 (en) Method and composition for the treatment of adenoviral ocular infections
HK1040906B (zh) 用於治療癌症的無效igf
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
UA32295A (uk) Спосіб лікування порушень фертильності у хворих на цукровий діабет
GB9818650D0 (en) Therapeutic compounds and methods of making and using the same
UA88862C2 (en) Glucagon-like peptide-1 analogs
UA34377A (uk) Спосіб терапії астенічного синдрому у хворих на хронічний алкоголізм
UA72871C2 (uk) Засіб для лікування та профілактики цукрового діабету та спосіб лікування
UA32254A (uk) Спосіб лікування хронічного пієлонефриту у хворих на цукровий діабет
CA2236269A1 (en) Selective .beta.3 adrenergic agonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees